Novo Nordisk Foundation invests $136m in new cell therapy facility
The Denmark-based Cellerator facility will manufacture cell therapies for clinical trials.
Interviews
What does CSRD mean for the pharmaceutical industry? ENGIE Impact explains
Q&A: How the Henrietta Lacks settlement challenges biotech’s view on ethics
Q&A: How can the US maintain access to essential drugs?
Q&A: How Big Pharma implements analytics in continuous manufacturing
Q&A: As RSV vaccine approvals loom, regulators need to devise vaccination strategies
Q&A: A decade on, what’s next for CAR-T therapies?
Q&A: Cleaning up the antibiotic resistance problem in dentistry
